Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting

Frontiers in Immunology(2022)10.3389/fimmu.2022.841107Source: DataRank Database

iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting is a research paper published in Frontiers in Immunology (2022). On theSindex it has a DataRank of 0. It has been cited 139 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access139 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 12.02)OA: goldTopics (94)Linked Datasets (12)DataCite Reuse (12)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Pooja Hor ORCID,Dan S. Kaufman ORCID,Benjamin Goldenson ORCID

Live enrichment

PubMed:35185932 PMC:PMC8851389 OpenAlex:https://openalex.org/W4210261363

NCI NIH HHS

Grant: U01 CA217885

National Institutes of Health

Grant: 5U01CA217885-03

A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic States

National Institutes of Health

California Institute of Regenerative Medicine

FWCI

12.02

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://www.frontiersin.org/articles/10.3389/fimmu.2022.841107/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2022.841107/pdf

journalhttps://doi.org/10.3389/fimmu.2022.841107

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35185932

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8851389

Fields of Study

CAR-T cell therapy researchPluripotent Stem Cells ResearchImmune Cell Function and Interaction0301 basic medicine0302 clinical medicine03 medical and health sciences

MeSH Terms

Receptors, Chimeric AntigenAnimalsHumansKiller Cells, NaturalNeoplasmsImmunotherapy, AdoptiveHematologic NeoplasmsInduced Pluripotent Stem Cells

Keywords

Induced pluripotent stem cellCancer researchCell therapyImmunologyBiologyMedicineStem cellEmbryonic stem cellCell biologyCell engineeringImmunotherapyNK cellChimeric Antigen Receptor (Car)Ipsc (Induced Pluripotent Stem Cells)Medical BiotechnologyAdoptiveStem Cell Research - Induced Pluripotent Stem Cell - Human (rcdc)Regenerative Medicine3105 Genetics (for-2020)Immunotherapy, AdoptiveAdoptive (mesh)Regenerative Medicine (rcdc)Stem Cell Research - Nonembryonic - HumanNeoplasms3206 Medical Biotechnology (for-2020)Receptors2.1 Biological and endogenous factorsAnimals (mesh)Killer Cells32 Biomedical and Clinical Sciences (for-2020)Stem Cell Research - Nonembryonic - Human (rcdc)3101 Biochemistry and cell biology (for-2020)CancerCancer (rcdc)Humans (mesh)Neoplasms (mesh)iPSCReceptors, Chimeric AntigenStem Cell Research - Induced Pluripotent Stem Cell - Humanchimeric antigen receptorHematologyInduced Pluripotent Stem Cells (mesh)Killer Cells, NaturalMedical MicrobiologyHematologic NeoplasmsNaturalChimeric Antigen (mesh)BiotechnologyHematologic Neoplasms (mesh)Oncology and CarcinogenesisStem Cell Research - Induced Pluripotent Stem Cell (rcdc)Induced Pluripotent Stem Cells6101107 Immunology (for)Biotechnology (rcdc)Rare Diseases (rcdc)Rare DiseasesGeneticsAnimalsHumans3204 Immunology (for-2020)Natural (mesh)Hematology (rcdc)Biomedical and Clinical SciencesStem Cell Research - Induced Pluripotent Stem Cell5.2 Cellular and gene therapies1108 Medical Microbiology (for)Chimeric AntigenImmunotherapy (rcdc)5.2 Cellular and gene therapies (hrcs-rac)2.1 Biological and endogenous factors (hrcs-rac)Cancer (hrcs-hc)RC581-607Stem Cell ResearchStem Cell Research (rcdc)Orphan Drug3211 Oncology and Carcinogenesis (for-2020)Biochemistry and cell biologyOrphan Drug (rcdc)Immunologic diseases. Allergy

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 6 of Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells

10.6084/m9.figshare.23520083.v1figshare

Additional file 6 of Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells

10.6084/m9.figshare.23520083figshare

Additional file 3 of Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells

10.6084/m9.figshare.23520071figshare

Additional file 2 of Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells

10.6084/m9.figshare.23520068.v1figshare

Additional file 2 of Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells

10.6084/m9.figshare.23520068figshare

Additional file 5 of Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells

10.6084/m9.figshare.23520077.v1figshare

Additional file 4 of Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells

10.6084/m9.figshare.23520074.v1figshare

Additional file 4 of Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells

10.6084/m9.figshare.23520074figshare

Additional file 1 of Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells

10.6084/m9.figshare.23520065.v1figshare

Additional file 3 of Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells

10.6084/m9.figshare.23520071.v1figshare

Additional file 5 of Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells

10.6084/m9.figshare.23520077figshare

Additional file 1 of Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells

10.6084/m9.figshare.23520065figshare

Related Papers (10)

Cancer statistics, 2019

Top 2%

8.8DataRank

CA: A Cancer Journal for Clinicians(2019)

co-cited

10.3322/caac.21551

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

N/A

5.4DataRank · unranked

New England Journal of Medicine(2020)

co-cited

10.1056/nejmoa1910607

Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group

N/A

3.5DataRank · unranked

npj Breast Cancer(2020)

co-cited

10.1038/s41523-020-0154-2

Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment

N/A

0.698DataRank · unranked

Cancer Cell(2020)

co-cited

10.1016/j.ccell.2020.10.015

Germline Sequencing DNA Repair Genes in 5545 Men With Aggressive and Nonaggressive Prostate Cancer

N/A

0.673DataRank · unranked

JNCI Journal of the National Cancer Institute(2020)

co-cited

10.1093/jnci/djaa132

Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer

N/A

0.657DataRank · unranked

European Urology(2020)

co-cited

10.1016/j.eururo.2020.06.033

Computationally Derived Image Signature of Stromal Morphology Is Prognostic of Prostate Cancer Recurrence Following Prostatectomy in African American Patients

N/A

0.631DataRank · unranked

Clinical Cancer Research(2020)

co-cited

10.1158/1078-0432.ccr-19-2659

Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)

N/A

0.510DataRank · unranked

Cancers(2020)

co-cited

10.3390/cancers12102831

Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

N/A

0.934DataRank · unranked

Nature Genetics(2021)

co-cited

10.1038/s41588-020-00748-0

Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer

N/A

6.3DataRank · unranked

Nature(2021)

co-cited

10.1038/s41586-021-04246-z

iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting

FAIR Checklist

Authors (3)

Funding (4 grants)

Impact

Open Access

Topics

Linked Datasets (12)

Annotations (Europe PMC)

Related Papers (10)